Propanc Biopharma, Inc. 正全力推进其核心候选药物PRP的临床开发进程,并将胰腺癌与卵巢癌的治疗研究作为首要战略方向。公司致力于通过创新疗法应对这些高致死率癌症的临床挑战。
Propanc Biopharma, Inc. 正全力推进其核心候选药物PRP的临床开发进程,并将胰腺癌与卵巢癌的治疗研究作为首要战略方向。公司致力于通过创新疗法应对这些高致死率癌症的临床挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.